FDA approves Enhertu as neoadjuvant, adjuvant treatment for breast cancer

The U.S. Food and Drug Administration has approved AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) for both the ...
Medscape

Adjuvant vs Neoadjuvant Therapy in NSCLC: Which Approach Offers the Best Chance for Cure?

Hello. It's Mark Kris from Memorial Sloan Kettering. Recently, I presented information about the published trials of neoadjuvant nivolumab chemotherapy vs chemotherapy, showing robust, disease-free ...
Medscape

Managing Lung Cancer With Neoadjuvant and Adjuvant Therapy

This transcript has been edited for clarity. Jacob Sands, MD: Hello. I'm Dr Jacob Sands, a thoracic medical oncologist at the Dana-Farber Cancer Institute. Welcome to Medscape's InDiscussion series on ...
The American Journal of Managed Care

Integrating Durvalumab and Atezolizumab Into Neoadjuvant and Adjuvant Sequencing Strategies for Resectable NSCLC

Experts weigh lung cancer perioperative immunotherapy trials, debating adjuvant nivolumab, ctDNA guidance, and chemo choices versus pembrolizumab data. This episode, titled Integrating Durvalumab and ...
The American Journal of Managed Care

FDA Approves Enhertu for 2 New Indications for Patients With HER2+ Early Breast Cancer

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...
ascopubs.org

Survival for Head and Neck Squamous Cell Carcinoma Treated With Versus Without Neoadjuvant Systemic Therapy: A National Propensity Score–Matched Analysis

Patients who received neoadjuvant systemic therapy followed by surgical resection for mucosal HNSCC in the US National Cancer Database (2004-2022) were evaluated using 1:5 propensity score matching to ...
Cancer Therapy Advisor

Enhertu Gains Two HER2-Positive Early Breast Cancer Indications

New approvals for fam-trastuzumab deruxtecan-nxki establish a potential new standard of care in the neoadjuvant and adjuvant settings for patients with HER2-positive early breast cancer.
MedPage Today on MSN

Blockbuster Drug Gets Breast Cancer Approvals in Curative Setting

New trastuzumab deruxtecan indications cover neoadjuvant and adjuvant treatment ...
Pharmabiz

AstraZeneca announces perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in EFS and OS in MIBC in phase III VOLGA ...

AstraZeneca announces perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in EFS and OS in MIBC in phase III VOLGA tr ...